A quantitative structure-activity relationship study on serotonin 5-HT6 receptor ligands: Indolyl and piperidinyl sulphonamides

SAR and QSAR in Environmental Research

Volumn 21, Issue 3, 2010, Pages 369-388

  Sharma, B K ^a   Singh, P ^a   Sarbhai, K ^a   Prabhakar, Y S ^b  

^a SK Government College   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Combinatorial protocol in multiple linear regression (CP MLR); DRAGON descriptors; Indolyl and piperidinyl sulphonamides; Partial least squares (PLS) analysis; Serotonin 5 HT6 receptor

Indexed keywords

AMIDES; BINDING ENERGY; LEAST SQUARES APPROXIMATIONS; TOPOLOGY;

BINDING AFFINITIES; COMBINATORIAL PROTOCOL IN MULTIPLE LINEAR REGRESSION; DESCRIPTORS; DRAGON DESCRIPTOR; INDOLYL AND PIPERIDINYL SULPHONAMIDE; MULTIPLE LINEAR REGRESSIONS; PARTIAL LEAST SQUARE ANALYSIS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP STUDIES; SEROTONIN 5-HT6 RECEPTOR; SULPHONAMIDES;

MULTIPLE LINEAR REGRESSION;

EID: 77953595579     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/10629361003773997     Document Type: Article

References (63)

1. A. Slassi, M. Isaac, and A. O'Brien, Recent progress in 5-HT6 receptor antagonists for the treatment of CNS diseases, Expert Opin. Ther. Pat. 12 (2002), pp. 513-527.
2. D. Hoyer and G.R. Martin, 5-HT receptor classification and nomenclature: towards a harmonization with the human genome, Neuropharmacology 36 (1997), pp. 419-428.
3. D. Hoyer, D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, E. Mylecharane, P.R. Saxena, and P.P.A. Humphrey, International union of pharmacology classification of receptors for 5- hydroxytryptamine (serotonin), Pharmacol. Rev. 46 (1994), pp. 157-204.
4. R. Kohen, M.A. Metcalf, N. Khan, T. Druck, K. Huebner, J.E. Lachowicz, H.Y. Meltzer, D.R. Sibley, B.L. Roth, and M.W. Hamblin, Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor, J. Neurochem. 66 (1996), pp. 47-56.
5. M. Ruat, E. Traiffort, J.-M. Arrang, J. Tardivel-Lacombe, J. Diaz, R. Leurs, and J.-C. Swartz, A novel serotonin (5-HT6) receptor: molecular cloning, localisation and stimulation of cAMP accumulation, Biochem. Biophys. Res. Commun. 193 (1993), pp. 269-276.
6. M. Sebben, H. Ansanay, J. Bockaert, and A. Dumuis, 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture, Neuroreport 5 (1994), pp. 2553-2557.
7. L.A. Dawson, H.Q. Nguyen, and P. Li, In vivo effects of the 5-HT6 antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate, British J. Pharmacol. 130 (2000), pp. 23-26.
8. L.A. Dawson, H.Q. Nguyen, and P. Li, The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus, Neuropsychopharmacology 25 (2001), pp. 662-668.
9. L.A. Dawson, H.Q. Nguyen, and P. Li, Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT6 receptor antagonist, Brain Res. Bull. 59 (2003), pp. 513-521.
10. L.P. Lacroix, L.A. Dawson, J.J. Hagan, and C.A. Heidbreder, 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex, Synapse 51 (2004), pp. 158-164.
11. C. Riemer, E. Borroni, B. Levet-Trafit, J.R. Martin, S. Poli, R.H. Porter, and M. Bos, Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist, J. Med. Chem. 46 (2003), pp. 1273-1276.
12. D.J. Healy and J.H. Meador-Woodruff, Ionotropic glutamate receptor modulation of 5-HT6 and 5-HT7 mRNA expression in rat brain, Neuropsychopharmacology 21 (1999), pp. 341-351.
13. Y. Minabe, Y. Shirayama, K. Hashimoto, C. Routledge, J.J. Hagan, and C.R. Ashby Jr., Effect of the acute and chronic administration of the selective 5-HT6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study, Synapse 52 (2004), pp. 20-28.
14. B.L. Roth, S.C. Craigo, M.S. Choudhary, A. Uluer, F.J. Monsma Jr, Y. Shen, H.Y. Meltzer, and D.R. Sibley, Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors, J. Pharmacol. Exp. Ther. 268 (1994), pp. 1403-1410.
15. F.J. Monsma, Y. Shen, R.P. Ward, M.W. Hamblin, and D.R. Sibley, Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs, Mol. Pharmacol. 43 (1993), pp. 320-327.
16. T. Shinkai, O. Ohmori, H. Kojima, T. Terao, T. Suzuki, and K. Abe, Association study of the 5-HT6 receptor gene in schizophrenia, Amer. J. Med. Genet. 88 (1999), pp. 120-122.
17. S.J. Tsai, H.J. Chiu, Y.C. Wang, and C.J. Hong, Association study of serotonin-6 receptor variant (C267T) with schizophrenia and aggressive behavior, Neurosci. Lett. 271 (1999), pp. 135-137.
18. I.R. Vogt, D. Shimron-Abarbanell, H. Neidt, J. Erdmann, S. Cichon, T.G. Schulze, D.J. Muller, W. Maier, M. Albus, M. Borrmann-Hassenbach, M. Knapp, M. Rietschel, P. Propping, and M.M. Nothen, Investigation of the human serotonin 6 [5-HT6] receptor gene in bipolar affective disorder and schizophrenia, Amer. J. Med. Genet. 96 (2000), pp. 217-221.
19. O. Ohmori, T. Shinkai, H. Hori, and J. Nakamura, Novel polymorphism in the 5Aˆ-upstream region of the human 5-HT6 receptor gene and schizophrenia, Neurosci. Lett. 310 (2001), pp. 17-20.
20. 125I]SB-258585, Synapse 45 (2002), pp. 191-199.
21. W.H. Wu, S.J. Huo, C.Y. Cheng, C.J. Hong, and S.J. Tsai, Association study of the 5-HT6 receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders, Neuropsychobiology 44 (2001), pp. 172-175.
22. D. Messina, G. Annesi, P. Serra, G. Nicoletti, A. Pasqua, F. Annesi, C. Tomaino, I.C. Ciro- Candiano, S. Carrideo, M. Caracciolo, P. Spadafora, M. Zappia, G. Savettieri, and A. Quattrone, Association of the 5-HT6 receptor gene polymorphism C267T with Parkinson's disease, Neurology 58 (2002), pp. 828-829.
23. J. Thome, W. Retz, M. Baader, B. Pesold, M. Hu, M. Cowen, N. Durany, G. Adler, F.A. Henn, and M. Rosler, Association analysis of HTR6 and HTR2A polymorphisms in Sporadic Alzheimer's disease, J. Neural Transm. 108 (2001), pp. 1175-1180.
24. H.C. Liu, C.J. Hong, C.Y. Liu, K.N. Lin, S.J. Tsai, T.Y. Liu, C.W. Chi, and P.N. Wang, Association analysis of the 5-HT6 receptor polymorphism C267T with depression in patients with Alzheimer's disease, Psychiatry Clin. Neurosci. 55 (2001), pp. 427-429.
25. M. Garcia-Alloza, W.D. Hirst, C.P. Chen, B. Laheras, P.T. Francis, and M.J. Ramirez, Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and noncognitive symptoms in Alzheimer's disease, Neuropsychopharmacology 29 (2004), pp. 410-416.
26. A.J. Sleight, F.G. Boss, M. Bos, B. Levet-Trafit, C. Riemer, and A. Bourson, Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors, British J. Pharmacol. 124 (1998), pp. 556-562.
27. S.M. Bromidge, A.M. Brown, S.E. Clarke, K. Dodgson, T. Gager, H.L. Grassam, P.M. Jeffrey, G.F. Joiner, F.D. King, D.N. Middlemiss, S.F. Moss, H. Newman, G. Riley, C. Routledge, and P. Wyman, 5-Chloro-N-(4-methoxy-3-piperazin-1-ylphenyl)-3-methyl-2-benzothiophenesulfona- mide (SB-271046): A potent, selective, and orally bioavailable 5-HT6 receptor antagonist, J. Med. Chem. 42 (1999), pp. 202-205.
28. R.A. Glennon, M. Lee, J.B. Rangisetty, M. Dukat, B.L. Roth, J.E. Savage, A. McBride, L. Rauser, L. Hufeisen, and D.K.H. Lee, 2-Substituted tryptamines: agents with selectivity for 5-HT6 serotonin receptors, J. Med. Chem. 43 (2000), pp. 1011-1018.
29. M.G.N. Russell, R.J. Baker, L. Barden, M.S. Beer, L. Bristow, H.B. Broughton, M. Knowles, G. McAllister, S. Patel, and J.L. Castro, N-Arylsulfonylindole derivatives as serotonin 5-HT6 receptor ligands, J. Med. Chem. 44 (2001), pp. 3881-3895.
30. J. Holenz, R. Merce, J.L. Diaz, X. Guitart, X. Codony, A. Dordal, G. Romero, A. Torrens, J. Mas, B. Andaluz, S. Hernandez, X. Monroy, E. Sanchez, E. Hernandez, R. Perez, R. Cubi, O. Sanfeliu, and H. Buschmann, Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands, J. Med. Chem. 48 (2005), pp. 1781-1795.
31. A. Torrens, J. Mas, A. Dordal, and M.A. Fisas, Compuestos sulfonamidicos derivados de benzoxazinona, supreparacion y uso como medicamentos. Spanish Patent Application ES 2003- 01812, July 30, 2003.
32. R. Todeschini, M. Lasagni, and E. Marengo, New molecular descriptors for 2D and 3D structures theory: Part 1, J. Chemometrics 8 (1994), pp. 263-272.
33. J. Galvez, R. Garcia-Domenech, J.V. de Julian-Ortiz, and R. Soler, Topological approach to drug design, J. Chem. Inf. Comput. Sci. 35 (1995), pp. 272-284.
34. J. Devillers and A.T. Balaban, Topological Indices and Related Descriptors in QSAR and QSPR, Gordon and Breach Science Publishers, Singapore,1999, p. 296.
35. R. Gozalbes, J.P. Doucet, and F. Derouin, Application of topological descriptors on QSAR and drug design: history and new trends, Curr. Drug Targets Infect. Disord. 2 (2002), pp. 93-102.
36. M.P. Gonzalez, C. Teran, M. Teijeira, P. Besada, and M.J. Gonzalez-Moa, BCUT descriptors to predicting affinity toward A3 adenosine receptors, Bioorg. Med. Chem. Lett. 15 (2005), pp. 3491-3495.
37. M.C. Bagchi, D. Mills, and S.C. Basak, Quantitative structure-activity relationship (QSAR) studies of quinolone antibacterials against M. fortuitum and M. megmatis using theoretical molecular descriptors, J. Mol. Model. 13 (2007), pp. 111-120.
38. L. Saiz-Urra, M.P. Gonzalez, and M. Teijeira, 2D-autocorrelation descriptors for predicting cytotoxicity of naphthoquinone ester derivatives against oral human epidermoid carcinoma, Bioorg. Med. Chem. 15 (2007), pp. 3565-3571.
39. A.M. Helguera, R.D. Combes, M.P. Gonzalez, and M.N. Cordeiro, Applications of 2D descriptors in drug design: a DRAGON tale, Curr. Top. Med. Chem. 8 (2008), pp. 1628-1655.
40. R. Kuhne, R.-U. Ebert, and G. Schuurmann, Chemical domain of QSAR models from atomcentered fragments, J. Chem. Inf. Model. 49 (2009), pp. 2660-2669.
41. R. Todeschini and V. Consonni, DRAGON software (version 1.11-2001), Milan, Italy.
42. B.L. Roth, S.C. Craigo, M.S. Choudhary, A. Uluer, F.J. Monsma Jr, Y. Shen, H.Y. Meltzer, and D.R. Sibley, Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors, J. Pharmacol. Exp. Ther. 268 (1994), pp. 1403-1410.
43. P.J. Munson and D. Robbard, LIGAND: A versatilecomputerized approach for characterization of ligand-binding systems, Anal. Biochem. 107 (1980), pp. 220-239.
44. Chemdraw Ultra 6.0 and Chem3D Ultra, Cambridge Soft Corporation, Cambridge, USA.
45. Y.S. Prabhakar, A combinatorial approach to the variable selection in multiple linearregression: analysis of Selwood et al. data set - a case study, QSAR Comb. Sci. 22 (2003), pp. 583-595.
46. S. Wold, Cross-validatory estimation of the number of components in factor and principal components models, Technometrics 20 (1978), pp. 397-405.
47. N. Kettaneh, A. Berglund, and S. Wold, PCA and PLS with very large data sets, Comput. Statist. Data Anal. 48 (2005), pp. 69-85.
48. L. Stahle and S. Wold, Multivariate data analysis and experimental design, in Biomedical Research, Progress in Medicinal Chemistry, Vol. 25, G.P. Ellis and W.B. West, eds., Elsevier Science Publishers, BV, The Netherlands, 1998, pp. 291-338.
49. S. Sharma, Y.S. Prabhakar, P. Singh, and B.K. Sharma, QSAR study about ATP-sensitive potassium channel activation of cromakalim analogues using CP-MLR approach, European J. Med. Chem. 43 (2008), pp. 2354-2360.
50. 0-uronamide, European J. Med. Chem. 44 (2009), pp. 1377-1382.
51. P. Singh, R. Kumar, B.K. Sharma, and Y.S. Prabhakar, Topological descriptors in modeling malonyl coenzyme A decarboxylase inhibitory activity: N-Alkyl-N(1,1,1,3,3,3-Hexafluoro-2- hydroxypropylphenyl)amide derivatives, J. Enzyme Inhib. Med. Chem. 24 (2009), pp. 77-85.
52. B.K. Sharma, S.K. Sharma, P. Singh, S. Sharma, and Y.S. Prabhakar, Modeling of vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitory activity of 2-Anilino-5-aryloxazoles using chemometric tools, J. Enzyme Inhib. Med. Chem. 24 (2009), pp. 86-93.
53. B.K. Sharma, P. Pilania, K. Sarbhai, P. Singh, and Y.S. Prabhakar, @Chemometric descriptors in modeling the carbonic anhydrase inhibition activity of sulfonamide and sulfamate derivatives, Mol. Divers. 14 (2010), pp. 371-384.
54. S.-S. So and M. Karplus, Three-dimensional quantitative structure-activity relationship from molecular similarity matrices and genetic neural networks. 1. Method and validation, J. Med. Chem. 40 (1997), pp. 4347-4359.
55. Y.S. Prabhakar, V.R. Solomon, R.K. Rawal, M.K. Gupta, and S.B. Katti, CP-MLR/PLS directed structure-activity modeling of the HIV-1 RT inhibitory activity of 2,3-Diaryl-1,3-thiazolidin-4-ones, QSAR Comb. Sci. 23 (2004), pp. 234-244.
56. H. Akaike, Information theory and an extension of the minimum likelihood principle, in Second International Symposium On Information Theory, B.N. Petrov and F. Csaki, eds., Akademiai Kiado, Budapest, 1973, pp. 267-281.
57. H. Akaike, A new look at the statistical identification model, IEEE Trans. Automat. Control AC-19 (1974), pp. 716-723.
58. H. Kubinyi, Variable selection in QSAR studies. I. An evolutionary algorithm, Quant. Struct.-Act. Relat. 13 (1994), pp. 285-294.
59. H. Kubinyi, Variable selection in QSAR studies. II. A highly efficient combination of systematic search and evolution, Quant. Struct.-Act. Relat. 13 (1994), pp. 393-401.
60. J. Friedman, Multivariate adoptive regression splines, in Technical Report No. 102, Laboratory for Computational Statistics, Department of Statistics, Stanford University, Stanford, USA, November 1988 (revised August 1990).
61. D.M. Hawkins, S.C. Basak, and D. Mills, Assessing model fit by cross-validation, J.Chem. Inf. Comput. Sci. 43 (2003), pp. 579-586.
62. P. Gramatica, Principles of QSAR models validation: internal and external, QSAR Comb. Sci. 26 (2007), pp. 694-701.
63. R.L. Lipnick, Outliers: their origin and use in the classification of molecular mechanisms of toxicity, Sci. Total Environ. 109 (1991), pp. 131-153.